NCT00182806View on ClinicalTrials.gov

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

July 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

gemcitabine hydrochloride

IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.

DRUG

irinotecan hydrochloride

IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00182806 - Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter